Los puntos clave no están disponibles para este artículo en este momento.
The addition of monoclonal antibodies against C. difficile toxins to antibiotic agents significantly reduced the recurrence of C. difficile infection. (ClinicalTrials.gov number, NCT00350298.)
Lowy et al. (Wed,) studied this question.